Prot #AG881-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/o

Project: Research project

Project Details

StatusFinished
Effective start/end date8/31/15 → 8/31/18

Funding

  • Novella Clinical, LLC (Prot #AG881-C-001 // Prot #AG881-C-001)
  • Agios Pharmaceuticals, Inc. (Prot #AG881-C-001 // Prot #AG881-C-001)